Caring Brands, Inc. (NASDAQ:CABR) Short Interest Up 281.9% in August

Caring Brands, Inc. (NASDAQ:CABR) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 23,442 shares, an increase of 281.9% from the August 15th total of 6,138 shares. Based on an average daily volume of 31,051 shares, the short-interest ratio is presently 0.8 days. Currently, 0.3% of the shares of the company are sold short.

Caring Brands Price Performance

NASDAQ CABR opened at $1.19 on Monday. The company has a quick ratio of 4.93, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The company has a market cap of $12.34 million and a PE ratio of -1.61. Caring Brands has a 52 week low of $0.71 and a 52 week high of $5.35. The firm’s 50-day simple moving average is $1.37 and its two-hundred day simple moving average is $1.18.

Caring Brands (NASDAQ:CABR) last posted its earnings results on Thursday, August 13th. The company reported ($0.10) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Caring Brands in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Caring Brands currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC purchased a new stake in Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent filing with the Securities & Exchange Commission.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.